Shemesh Eyal, Reynolds Deborah, Sidhu Jasleen, Duncan-Park Sarah, Tejiram Rebecca A, Davison Beth A, Takagi Koji, Edwards Chris, Rubinstein David, Annunziato Rachel A, Cotter Gad
Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Place, New York, NY, 10029, USA.
Mindich Child Health and Development Institute, Precision Behavioral Medicine Program, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Sci Rep. 2025 Aug 12;15(1):29449. doi: 10.1038/s41598-025-14968-z.
Increased variability in systolic blood pressure, expressed as the coefficient of variation (BPCoV), is associated with poor cardiovascular outcomes. Variability could be due to episodic non-adherence to medical recommendations in some patients. Reports of targeted attempts to mitigate such variation are lacking. A behavioral intervention targeted at patients with initially high BPCoV may decrease variability. In this single-site, single arm prospective proof-of-concept trial, an electronic health record review identified patients with excessive variability (BPCov>10%). Enrolled patients received a blood pressure monitor and a remotely delivered behavioral intervention for 3 months. The primary outcome was mean blood pressure variability before versus after the intervention. Of 551 initially screened patients, 107 (19.4%) met the BPCoV criteria, and 25 consented (6 females and 19 males, mean age 64.24 years). Average BPCoV for the 6 months pre-enrollment was 12.96 (SD=2.11) compared to 7.02 (SD=3.54) during intervention (p<0.001). Other variability metrics also improved. Sensitivity analyses (different timeframes, using measurements obtained in the clinic vs. home monitor) all showed significant improvement. This proof-of-concept trial suggests that patients with high systolic blood pressure variability can successfully engage in a remotely delivered behavioral intervention, and that such an intervention can reduce such variability. Trial Registration: NCT05814562, ClinicalTrials.gov.
收缩压变异性增加,以变异系数(BPCoV)表示,与不良心血管结局相关。变异性可能是由于一些患者偶尔不遵守医学建议所致。目前缺乏针对减轻这种变异性的针对性尝试的报告。针对初始BPCoV较高的患者进行行为干预可能会降低变异性。在这项单中心、单臂前瞻性概念验证试验中,通过电子健康记录审查确定了变异性过高(BPCov>10%)的患者。入选患者接受了血压监测仪和为期3个月的远程行为干预。主要结局是干预前后的平均血压变异性。在最初筛查的551名患者中,107名(19.4%)符合BPCoV标准,25名患者同意参与(6名女性和19名男性,平均年龄64.24岁)。入组前6个月的平均BPCoV为12.96(标准差=2.11),而干预期间为7.02(标准差=3.54)(p<0.001)。其他变异性指标也有所改善。敏感性分析(不同时间框架,使用在诊所与家庭监测仪获得的测量值)均显示有显著改善。这项概念验证试验表明,收缩压变异性高的患者能够成功参与远程行为干预,并且这种干预可以降低这种变异性。试验注册:NCT05814562,ClinicalTrials.gov。